FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090809780> ?p ?o ?g. }

• W2090809780 endingPage "81U" @default.
• W2090809780 startingPage "74U" @default.
• W2090809780 abstract "Crystalline nicotinic acid (immediate-release niacin) is effective therapy for lipoprotein regulation and cardiovascular risk reduction. However, inconvenient regimens and unpleasant side effects decrease compliance. Sustained-release formulations designed to circumvent these difficulties increase hepatotoxicity. Niaspan, a new US Food and Drug Administration (FDA)-approved, once-daily, extended-release form, has been found effective and safe in short-term trials. The long-term efficacy and safety of Niaspan lipid monotherapy was studied in 517 patients (aged 21–75 years) for ≤96 weeks in dosages ≤3,000 mg/day. Primary efficacy endpoints were low-density lipoprotein (LDL) cholesterol and apolipoprotein B (apo B) changes from baseline; secondary efficacy endpoints were changes in total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, lipoprotein(a), and total cholesterol/HDL-cholesterol ratio; safety data included adverse events and laboratory values over the 2-year study period. LDL-cholesterol levels decreased significantly: 18% at week 48 and 20% at week 96; apo B reduction was similar (16% decrease at week 48 and 19% at week 96). Large elevations in HDL cholesterol (26%, week 48; 28%, week 96) allowed only modest decreases in total cholesterol (12% and 13%, respectively), whereas total cholesterol/HDL-cholesterol ratio decreased by almost one third. Triglyceride and lipoprotein(a) levels were decreased by 27% and 30%, respectively (week 48), and by 28% and 40%, respectively (week 96). All changes from baseline were significant (p <0.001). Niaspan was generally well tolerated, although flushing was common (75%); however, there was a progressive decrease in flushing with time from 3.3 episodes in the first month to ≤1 episode by week 48. Aspirin was used by one third of patients before Niaspan dosing to minimize flushing episodes. Although serious adverse events occurred in about 10% of patients, none were considered probably or definitely related to Niaspan. Adverse events in general varied widely, but their true relation to the study drug is difficult to ascertain without a placebo (control) group. No deaths occurred. There were statistically significant changes in hepatic transaminases, alkaline phosphatase, direct bilirubin, phosphorus, glucose, amylase, and uric acid. However, these changes were mostly small and are not likely to be biologically or clinically significant (the decrease in phosphorus is a new finding in niacin therapy). No myopathy was observed. Thus, this long-term study confirms the earlier short-term findings that Niaspan is safe and effective as monotherapy in plasma lipoprotein regulation." @default.
• W2090809780 created "2016-06-24" @default.
• W2090809780 creator A5003623773 @default.
• W2090809780 creator A5008726377 @default.
• W2090809780 creator A5016633003 @default.
• W2090809780 creator A5051454169 @default.
• W2090809780 creator A5062976315 @default.
• W2090809780 creator A5076558291 @default.
• W2090809780 creator A5090299640 @default.
• W2090809780 date "1998-12-01" @default.
• W2090809780 modified "2023-09-27" @default.
• W2090809780 title "Efficacy and safety of an extended-release niacin (niaspan): a long-term study" @default.
• W2090809780 cites W1981670728 @default.
• W2090809780 cites W1982486828 @default.
• W2090809780 cites W1988179941 @default.
• W2090809780 cites W1998010052 @default.
• W2090809780 cites W2000921060 @default.
• W2090809780 cites W2015873233 @default.
• W2090809780 cites W2044397157 @default.
• W2090809780 cites W2070855777 @default.
• W2090809780 cites W2070999659 @default.
• W2090809780 cites W2078578691 @default.
• W2090809780 cites W2089753969 @default.
• W2090809780 cites W2103493042 @default.
• W2090809780 cites W2113434143 @default.
• W2090809780 cites W2115572248 @default.
• W2090809780 cites W2155655406 @default.
• W2090809780 cites W2325833506 @default.
• W2090809780 cites W2725187802 @default.
• W2090809780 cites W4233804225 @default.
• W2090809780 cites W4244668309 @default.
• W2090809780 cites W4362068863 @default.
• W2090809780 doi "https://doi.org/10.1016/s0002-9149(98)00731-0" @default.
• W2090809780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9915666" @default.
• W2090809780 hasPublicationYear "1998" @default.
• W2090809780 type Work @default.
• W2090809780 sameAs 2090809780 @default.
• W2090809780 citedByCount "230" @default.
• W2090809780 countsByYear W20908097802012 @default.
• W2090809780 countsByYear W20908097802013 @default.
• W2090809780 countsByYear W20908097802014 @default.
• W2090809780 countsByYear W20908097802015 @default.
• W2090809780 countsByYear W20908097802016 @default.
• W2090809780 countsByYear W20908097802017 @default.
• W2090809780 countsByYear W20908097802018 @default.
• W2090809780 countsByYear W20908097802019 @default.
• W2090809780 countsByYear W20908097802020 @default.
• W2090809780 countsByYear W20908097802021 @default.
• W2090809780 countsByYear W20908097802022 @default.
• W2090809780 crossrefType "journal-article" @default.
• W2090809780 hasAuthorship W2090809780A5003623773 @default.
• W2090809780 hasAuthorship W2090809780A5008726377 @default.
• W2090809780 hasAuthorship W2090809780A5016633003 @default.
• W2090809780 hasAuthorship W2090809780A5051454169 @default.
• W2090809780 hasAuthorship W2090809780A5062976315 @default.
• W2090809780 hasAuthorship W2090809780A5076558291 @default.
• W2090809780 hasAuthorship W2090809780A5090299640 @default.
• W2090809780 hasConcept C126322002 @default.
• W2090809780 hasConcept C134018914 @default.
• W2090809780 hasConcept C162156334 @default.
• W2090809780 hasConcept C197934379 @default.
• W2090809780 hasConcept C2778163477 @default.
• W2090809780 hasConcept C2778913445 @default.
• W2090809780 hasConcept C2780072125 @default.
• W2090809780 hasConcept C2780092750 @default.
• W2090809780 hasConcept C2780541478 @default.
• W2090809780 hasConcept C62746215 @default.
• W2090809780 hasConcept C71924100 @default.
• W2090809780 hasConceptScore W2090809780C126322002 @default.
• W2090809780 hasConceptScore W2090809780C134018914 @default.
• W2090809780 hasConceptScore W2090809780C162156334 @default.
• W2090809780 hasConceptScore W2090809780C197934379 @default.
• W2090809780 hasConceptScore W2090809780C2778163477 @default.
• W2090809780 hasConceptScore W2090809780C2778913445 @default.
• W2090809780 hasConceptScore W2090809780C2780072125 @default.
• W2090809780 hasConceptScore W2090809780C2780092750 @default.
• W2090809780 hasConceptScore W2090809780C2780541478 @default.
• W2090809780 hasConceptScore W2090809780C62746215 @default.
• W2090809780 hasConceptScore W2090809780C71924100 @default.
• W2090809780 hasIssue "12" @default.
• W2090809780 hasLocation W20908097801 @default.
• W2090809780 hasLocation W20908097802 @default.
• W2090809780 hasOpenAccess W2090809780 @default.
• W2090809780 hasPrimaryLocation W20908097801 @default.
• W2090809780 hasRelatedWork W1976602105 @default.
• W2090809780 hasRelatedWork W1981345773 @default.
• W2090809780 hasRelatedWork W1993860810 @default.
• W2090809780 hasRelatedWork W2004682325 @default.
• W2090809780 hasRelatedWork W2020629107 @default.
• W2090809780 hasRelatedWork W2033921535 @default.
• W2090809780 hasRelatedWork W2044844051 @default.
• W2090809780 hasRelatedWork W2063677317 @default.
• W2090809780 hasRelatedWork W2068768710 @default.
• W2090809780 hasRelatedWork W2072909849 @default.
• W2090809780 hasVolume "82" @default.
• W2090809780 isParatext "false" @default.
• W2090809780 isRetracted "false" @default.
• W2090809780 magId "2090809780" @default.

• next